SLAK-1, a proposed antibody-conjugated illudin analogue that selectively targets breast cancer<sup>1</sup>
Bibliographic record
Abstract
Our improved understanding behind the molecular mechanisms of tumorigenesis has facilitated the development of novel treatments for cancer. These are often small molecule natural products which have potent cytotoxic activity that inhibit the growth of cancerous cells. However, these chemotherapeutic drugs often have multiple biochemical targets that make it difficult to selectively target cancer cells. Antibody-Drug Conjugates (ADC) are cytotoxic agents that are chemically attached to monoclonal antibodies that target cancer-specific antigens. ADCs using the humanized antibody trastuzumab can facilitate the internalization of the drug by first binding to the human epidermal growth factor receptor 2 (HER2) which are over expressed on the surface of breast cancer cells in aggressive tumour types. With a lower risk of off-target side-effects, we present the use of a more potent cytotoxic agent with dual anticancer modes of action known as the illudin--a novel sesquiterpene that is derived from Omphalotus mushrooms with high therapeutic value. We first propose chemical modifications of illudin analogues to maximize both affinity to glutathione reductase and DNA damaging ability. By analyzing the chemical mechanisms of cytotoxicity and carrying out protein-docking simulations, an optimized illudin analogue can be generated. We then propose the construction of SLAK-1, an ADC that consists of a HER2 targeting antibody (Trastuzumab) and an illudin analogue that are attached to each other via a non-reducible thioether linker (SMCC). L’amélioration de notre compréhension vis-à-vis les mécanismes moléculaires tumorigenèse à faciliter le développement de nouveaux traitements pour le cancer. Ce sont habituellement de petits produits naturels qui détiennent une activité cytotoxique puissante inhibant la croissance de cellules cancéreuses. Toutefois, ces médicaments chimiothérapeutiques ont souvent de multiples cibles biochimiques ce qui rend difficile de cibler sélectivement les cellules cancéreuses. Les conjugués anticorps-médicament (ADC = antibody-drug conjugate) sont des agents cytotoxiques qui sont liés chimiquement à des anticorps monoclonaux qui ciblent à leur tour des antigènes spécifiques au cancer. L’ADC utilisant l’anticorps humain Trastuzumab peut faciliter l’internalisation du médicament en se liant tout d’abord au récepteur du facteur de croissance épidermique humain 2 (HER2) qui sont surexprimés à la surface des cellules du cancer du sein dans des tumeurs de types agressifs. Avec un risque plus faible d’effets secondaires hors cible, on présente l’utilisation d’un agent cytotoxique plus puissant avec une double action anticancéreuse connu sous le nom d’illudine – un nouveau sesquiterpène dérivé du champignon Omphalotus qui détient une haute valeur thérapeutique. Nous proposons d'abord des modifications chimiques à aux analogues d’illudine afin de maximiser à la fois affinité à la réductase glutathion et à sa capacité à endommager l'ADN. En analysant les mécanismes chimiques de la cytotoxicité et en menant des simulations d’amarrage de protéines (« docking »), un analogue d’illudine optimisé peut être généré. Nous proposons ensuite la construction de SLAK-1, un ADC qui consiste d'un anticorps ciblant HER2 (Trastuzumab) et un analogue d’illudine qui sont liés entre-elles par un lien thioéther non réductible (SMCC).
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.001 | 0.003 |
| Science and technology studies | 0.000 | 0.002 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".